Skip to main content

Glaucoma clinical trials at UCSF

4 in progress, 3 open to eligible people

Glaucoma is an eye condition that can cause vision loss. UCSF is running trials to see if low-energy SLT therapy works as well as standard energy. We're also looking at whether smaller eye drops can help glaucoma patients. Another study checks the impact of a Glaucoma Drainage Device on eye cells.

Showing trials for
  • Clarifying the Optimal Application of SLT Therapy Trial

    open to eligible people ages 18 years and up

    The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.

    San Francisco, California and other locations

  • Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

    open to eligible people ages 18 years and up

    Glaucoma is the leading cause of irreversible blindness worldwide. Previous studies demonstrate that smaller eye drops used in the treatment of glaucoma are just as efficacious as their larger counterparts. The proposed study hopes to demonstrate the non-inferiority of using Nanodropper to lower intraoccular pressure (IOP) in glaucoma patients compared to standard of care eye drops.

    San Francisco, California

  • Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial

    open to eligible people ages 18 years and up

    Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE) is a multi-center, outcome-masked, randomized clinical trial. The purpose of this study is to compare glaucoma drainage device implantation in the anterior chamber (front part of the eye) and sulcus (small space between iris and front chamber of the eye) in efforts to minimize cell loss in the eye.

    San Francisco, California and other locations

  • App-based Instructional Platform to Improve Eye Drop Recall

    Sorry, not yet accepting patients

    The goal of this interventional study is to assess whether an in-office, language-concordant instructional app improves drop regimen recall in a population of glaucoma patients who are on multi-drop regimens. Participants will be divided into two groups -- those who use the app and those who do not. The app will have narrated information regarding the drop regimen, a quiz to test understanding of the regimen, and will enable a graphical printout of the eye drops and schedule. At one month, both groups will be assessed on their eye drop regimen recall.

    San Francisco, California

Our lead scientists for Glaucoma research studies include .

Last updated: